Literature DB >> 9517955

In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae.

K Izumikawa1, Y Hirakata, T Yamaguchi, R Yoshida, H Tanaka, H Takemura, S Maesaki, K Tomono, M Kaku, K I Izumikawa, S Kamihira, S Kohno.   

Abstract

The in vitro activities of quinupristin-dalfopristin and streptogramin RPR 106972 were determined with 44 strains of Mycoplasma pneumoniae and compared to those of macrolides, minocycline, and quinolones. All isolates tested were highly susceptible to macrolides and to quinupristin-dalfopristin (MIC at which 90% of the isolates are inhibited [MIC90], 0.0625 microg/ml), followed by RPR 106972 (MIC90, 0.5 microg/ml), quinolones, and minocycline.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9517955      PMCID： PMC105521     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO.

Authors:  R M CHANOCK; L HAYFLICK; M F BARILE
Journal:  Proc Natl Acad Sci U S A       Date:  1962-01-15       Impact factor: 11.205

Review 2.  Streptogramins. A unique class of antibiotics.

Authors:  J C Pechère
Journal:  Drugs       Date:  1996       Impact factor: 9.546

3.  MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 4.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

5.  The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens.

Authors:  J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1994-04       Impact factor: 5.790

6.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.

Authors:  M Kaku; K Ishida; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; K Tomono; N Suyama
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Authors:  T S Lucier; K Heitzman; S K Liu; P C Hu
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  [Treatment of community-acquired pneumonia by pristinamycin (Pyostacine 500). Results of a non comparative open study].

Authors:  P Petitpretz; J C Guerin; G Nouvet; R Poirier; F Portier; J Vergeret; P Fraysse; J B Vercken
Journal:  Rev Pneumol Clin       Date:  1994
View more
  3 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan.

Authors:  T Yamaguchi; Y Hirakata; K Izumikawa; Y Miyazaki; S Maesaki; K Tomono; Y Yamada; S Kamihira; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.